Romain Neugebauer1, Katherine A Levandoski2, Zheng Zhu1, Monica Sokil1, Mary-Margaret Chren3, Gary D Friedman1, Maryam M Asgari4. 1. Division of Research, Kaiser Permanente Northern California, Oakland, California. 2. Department of Dermatology, Massachusetts General Hospital, and Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts. 3. Department of Dermatology, University of California, San Francisco, California. 4. Division of Research, Kaiser Permanente Northern California, Oakland, California; Department of Dermatology, Massachusetts General Hospital, and Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts. Electronic address: harvardskinstudies@partners.org.
Abstract
BACKGROUND: The most widely used topical agents for the field-based treatment of multiple actinic keratoses (AKs) are 5-fluorouracil and imiquimod, but their comparative effectiveness has not been assessed in a real-world setting. OBJECTIVE: We compared the effectiveness of 5-fluorouracil and imiquimod in reducing risk for subsequent AKs in a large, integrated health care delivery system in northern California. METHODS: In this cohort study, we identified adult health plan members who had an AK diagnosed in 2007 and who subsequently filled a prescription for 5-fluorouracil or imiquimod (N = 5700). We followed subjects for subsequent AKs identified by the International Classification of Diseases codes and estimated the 2-year (short-term) and 5-year (long-term) differences in cumulative risk while controlling for potential confounding by pretreatment variables. RESULTS: 5-Fluorouracil reduced the short-term incidence of subsequent AKs (cumulative risk difference -4.54% [95% confidence interval, -7.91% to -1.17%]), but there was no statistically significant evidence of a long-term decreased risk (cumulative risk difference -1.43% [95% confidence interval, -3.43% to 0.05%]) compared with that with imiquimod. LIMITATIONS: This is a retrospective study with limited ascertainment of all relevant potential confounding variables. CONCLUSION: We found that 5-fluorouracil appeared to be significantly more effective than imiquimod in the short-term, but not long-term, prevention of subsequent AKs.
BACKGROUND: The most widely used topical agents for the field-based treatment of multiple actinic keratoses (AKs) are 5-fluorouracil and imiquimod, but their comparative effectiveness has not been assessed in a real-world setting. OBJECTIVE: We compared the effectiveness of 5-fluorouracil and imiquimod in reducing risk for subsequent AKs in a large, integrated health care delivery system in northern California. METHODS: In this cohort study, we identified adult health plan members who had an AK diagnosed in 2007 and who subsequently filled a prescription for 5-fluorouracil or imiquimod (N = 5700). We followed subjects for subsequent AKs identified by the International Classification of Diseases codes and estimated the 2-year (short-term) and 5-year (long-term) differences in cumulative risk while controlling for potential confounding by pretreatment variables. RESULTS:5-Fluorouracil reduced the short-term incidence of subsequent AKs (cumulative risk difference -4.54% [95% confidence interval, -7.91% to -1.17%]), but there was no statistically significant evidence of a long-term decreased risk (cumulative risk difference -1.43% [95% confidence interval, -3.43% to 0.05%]) compared with that with imiquimod. LIMITATIONS: This is a retrospective study with limited ascertainment of all relevant potential confounding variables. CONCLUSION: We found that 5-fluorouracil appeared to be significantly more effective than imiquimod in the short-term, but not long-term, prevention of subsequent AKs.
Authors: Lindsey Warino; Mark Tusa; Fabian Camacho; Hoa Teuschler; Alan B Fleischer; Steven R Feldman Journal: Dermatol Surg Date: 2006-08 Impact factor: 3.398
Authors: H J Kolb; G Socié; T Duell; M T Van Lint; A Tichelli; J F Apperley; E Nekolla; P Ljungman; N Jacobsen; M van Weel; R Wick; M Weiss; H G Prentice Journal: Ann Intern Med Date: 1999-11-16 Impact factor: 25.391
Authors: Michael J Silverberg; Wendy Leyden; E Margaret Warton; Charles P Quesenberry; Eric A Engels; Maryam M Asgari Journal: J Natl Cancer Inst Date: 2013-01-04 Impact factor: 13.506
Authors: David R Bickers; Henry W Lim; David Margolis; Martin A Weinstock; Clifford Goodman; Eric Faulkner; Ciara Gould; Eric Gemmen; Tim Dall Journal: J Am Acad Dermatol Date: 2006-09 Impact factor: 11.527
Authors: Sarah N Robinson; Michael S Zens; Ann E Perry; Steven K Spencer; Eric J Duell; Margaret R Karagas Journal: J Invest Dermatol Date: 2013-01-23 Impact factor: 8.551